Comparative Pharmacology
Head-to-head clinical analysis: SULFACEL 15 versus SULFAIR 10.
Peer-Reviewed Evidence
Head-to-head clinical analysis: SULFACEL 15 versus SULFAIR 10.
SULFACEL-15 vs SULFAIR 10
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Sulfacetamide inhibits bacterial dihydropteroate synthase, blocking para-aminobenzoic acid (PABA) incorporation into dihydrofolate, thereby inhibiting folate synthesis and bacterial growth.
Bacteriostatic inhibitor of dihydropteroate synthase, blocking folic acid synthesis in susceptible bacteria.
Adults: 15 mg/kg orally every 6 hours for 10 days; maximum single dose 1 g.
5 mg orally once daily, taken at bedtime.
None Documented
None Documented
Expected ~6-9 hours based on related sulfacetamide; however, no specific data for SULFACEL-15. Clinical context: prolonged in renal impairment.
Terminal elimination half-life of 8-12 hours in adults with normal renal function (CrCl >60 mL/min); extends to 20-30 hours in severe renal impairment (CrCl <30 mL/min), requiring dose adjustment.
Renal: ~85-90% unchanged; Biliary/Fecal: ~5-10% (metabolites and unchanged drug); ~5% eliminated via feces following biliary secretion.
Renal excretion of unchanged drug (approximately 70-80%) and hepatic metabolism (20-30% as metabolites). Fecal elimination is minimal (<5%).
Category C
Category C
Antibiotic (Sulfonamide)
Antibiotic (Sulfonamide)